Who should govern a national research commons?
A national sponsor-support program could be housed within a defined federal grant authority or run through competitively funded nonprofit centers subject to transparent rules. Congress should ask NIH, FDA and OHRP for technical assistance while preserving existing boundaries: FDA regulates relevant medical products and investigations; OHRP oversees applicable HHS human research requirements; NIH may support scientific infrastructure under its authorities. F01F10
Governance should include practicing clinical investigators, trial methodologists, independent statisticians, research participants, privacy engineers, laboratories, ethicists and people familiar with small-sponsor operations. Boards should disclose financial interests, recuse conflicted decision-makers and publish aggregate outcomes. No private peptide vendor should get an implicit exclusive right to sponsor, judge or market its own claimed findings.
Funding conditions could require public methods materials, accessible support for non-university investigators, documented project classification and an incident reporting process. A nonprofit or research-service entity is not by virtue of its charter a federal regulator; its authority must derive from lawful contract, grant conditions or statute.
Access to independent review
Independent IRBs already exist, and relevant FDA/HHS regulations specify review structures and expedited or exempt routes. A small-sponsor assistance service can reduce confusion by publishing eligibility decision tools, a directory of available review bodies, standard contracts and understandable cost disclosures. A reform should not claim it created expedited review that is already permitted. F09F10
Where cooperative research falls within the HHS single-IRB provisions, reliance agreements define the relationship among institutions and review bodies. State and local context may still be relevant, including legal age, professional duties and privacy requirements. A distributed research organization should be explicit about who is engaged in research and which obligations stay local. F24
Congress may consider funding access to qualified review or requiring agencies to consider specific proportionate methods, but a new exception would need defined risk criteria and genuine accountability. The difficulty of finding affordable ethics services is a worthy policy issue even when the underlying review standard is justified.
Sponsor duties are a substantive legal responsibility
Under the IND framework, the sponsor is responsible for selecting investigators, monitoring progress, ensuring adequate control of the investigational article, and taking required action on safety and reporting. Some duties may be transferred by written agreement under §312.52. A private contract cannot be assumed to transfer every independently imposed duty or erase a regulator's authority. F04F05F06
A sponsor-support commons could supply qualified monitoring, statistical services and data infrastructure to a single-person sponsor, but it must document which tasks it actually performs and what evidence is returned to the sponsor. A platform showing green dashboard states is not proof that safety events were reviewed or records are complete.
The scientific quality gate should test protocol coherence, identifiable endpoints, methods of recruitment, risk analysis, material provenance, adverse-event escalation, data retention and result reporting. Projects that are merely opinion discussions should not be misclassified as clinical research; projects assigning a substance should not avoid review by calling them citizen science.
Public transparency and scientific autonomy
The initiative could publish redacted, aggregate records of regulatory determinations and common application problems, helping later applicants learn from actual precedents. Each decision would identify its legal scope and applicable facts, with commercially confidential or private information protected. Such a system is only meaningful if it has version control, a response clock and a process for correcting mistakes.
Research independence means allowing unfavorable results, criticism of the initiative, alternate legal theories and null experimental outcomes to remain discoverable. Financial supporters and product manufacturers should not control which studies or findings are published. A scientific integrity charter can distinguish legitimate moderation from suppression of contradictory evidence.
A transparent public advisory body could recommend future amendments based on an annual report: applicant access, review delays, participant comprehension, safety events, published results and effects on small-investigator participation. Congress can use these findings to adjust the system rather than assuming the first version is perfect.
A defensible first-year governance charter
The first year should prioritize a formal board charter, conflict registry, independent scientific review template, privacy governance rules, trial-methods training, complaint-handling procedure and version-controlled source library. These deliverables are concrete and measurable even before Congress enacts new investigational permissions.
A governance audit should demonstrate that every claimed certification or status corresponds to a documented actor and actual action. Where no licensed counsel has reviewed a bill or no IRB has approved a protocol, the public website should not imply otherwise. The movement can still advocate forcefully while keeping the research record intact.